Articles related to LYMPHOMA

In a recent phase 3 trial, the addition of brentuximab vedotin to standard chemotherapy not only achieved a notable improvement in 3-year event-free survival rates for pediatric Hodgkin’s lymphoma patients but also maintained a comparable safety profile, underscoring the therapeutic potential of targeted treatments in this population.

Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.

The POLARIX trial reveals polatuzumab vedotin with R-CHP as a promising first-line therapy for DLBCL, showing a 27% reduction in the risk of progression, relapse, or death and a progression-free survival rate of 76.7% at 2 years.

This case study explores a rare instance of intravascular large B-cell lymphoma, highlighting the diagnostic challenges and treatment outcomes.

Explore the profound impact of Social Determinants of Health on mantle cell lymphoma outcomes and the potential of novel therapies in reducing these disparities.

The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.